# A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC

> **NCT05386888** · PHASE2 · COMPLETED · sponsor: **Genfleet Therapeutics (Shanghai) Inc.** · enrollment: 65 (actual)

## Conditions studied

- NSCLC, Stage III

## Interventions

- **DRUG:** GFH018
- **DRUG:** Toripalimab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Pemetrexed
- **RADIATION:** Thoracic Radiation Therapy (TRT)
- **DRUG:** GFH018

## Key facts

- **NCT ID:** NCT05386888
- **Lead sponsor:** Genfleet Therapeutics (Shanghai) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-09
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386888, "A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05386888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*